298 related articles for article (PubMed ID: 15068398)
21. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
22. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
24. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Shah NT; Miller VA
Clin Lung Cancer; 2003 Nov; 5(3):182-6. PubMed ID: 14667275
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
27. Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Rothschild S; Bucher SE; Bernier J; Aebersold DM; Zouhair A; Ries G; Lombrieser N; Lippuner T; Lütolf UM; Glanzmann C; Ciernik IF
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):126-32. PubMed ID: 20646869
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib therapy for non-small cell lung cancer.
Birnbaum A; Ready N
Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
[TBL] [Abstract][Full Text] [Related]
29. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
Pizzo B
Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
31. Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.
Schütte W; Nagel S; Schaedlich S; Brust D; Blankenburg T
Onkologie; 2005 Apr; 28(4):195-8. PubMed ID: 15840967
[TBL] [Abstract][Full Text] [Related]
32. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
33. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V
Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
36. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
Araki J; Okamoto I; Suto R; Ichikawa Y; Sasaki J
Lung Cancer; 2005 Apr; 48(1):141-4. PubMed ID: 15777982
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?
Fujiwara K; Kiura K; Gemba K; Ogata Y; Hotta K; Kishino D; Tabata M; Ueoka H; Tanimoto M
Anticancer Res; 2005; 25(1B):547-9. PubMed ID: 15816627
[TBL] [Abstract][Full Text] [Related]
39. Gefitinib for the treatment of non-small-cell lung cancer.
Hida T; Ogawa S; Park JC; Park JY; Shimizu J; Horio Y; Yoshida K
Expert Rev Anticancer Ther; 2009 Jan; 9(1):17-35. PubMed ID: 19105704
[TBL] [Abstract][Full Text] [Related]
40. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
